Tildrakizumab: short-term efficacy and safety in real clinical practice

FI: 3,204
Type: Letter

Home · Ee11-Immune-mediated Skin Diseases (Emerging)

Artículo original

Year: 2022

Brands

Galan-Gutierrez, M; Freire, LRF; Ruiz-Villaverde, R

Magazine

Title: INTERNATIONAL JOURNAL OF DERMATOLOGY

Quartile

Q2